TITLE

Specialty pharmacies and other restricted drug distribution systems: Financial and safety considerations for patients and health-system pharmacists

AUTHOR(S)
Kirschenbaum, Bonnie E.
PUB. DATE
December 2009
SOURCE
American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS13
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. To discuss the role of restricted drug distribution systems in the implementation of risk evaluation and mitigation strategies (REMS), health-system pharmacists’ concerns associated with the use of specialty pharmacies and other restricted drug distribution systems, reimbursement policies for high-cost specialty drugs, supply chain models for traditional and specialty drugs, and emerging trends in the management of and reimbursement for specialty pharmaceuticals. Summary. Restricted drug distribution systems established by pharmaceutical manufacturers, specialty pharmacies, or other specialty suppliers may be a component of REMS, which are required by the Food and Drug Administration for the management of known or potential serious risks from certain drugs. Concerns of health-system pharmacists using specialty suppliers include access to pharmaceuticals, operational challenges, product integrity, financial implications, continuity of care, and patient safety. An ambulatory care patient taking a specialty drug product from home to a hospital outpatient clinic or inpatient setting for administration, a practice known as “brown bagging,” raises concerns about product integrity and institutional liability. An institution’s finances, tolerance for liability, and ability to skillfully manage the processes involved often determine its choice between an approach that prohibits brown bagging but is costly and one that permits the practice under certain conditions and is less costly. The recent shift from a traditional supply chain model to a specialty pharmacy supply chain model for high-cost pharmaceuticals has the potential to increase pharmaceutical costs for health systems. A dialogue is needed between health-system pharmacists and group purchasing organizations to address the latter’s role in mitigating the financial implications of this change and to help clarify the safety issues. Some health plans have shifted part of the cost of expensive drugs to patients by establishing a fourth tier of drugs with a large copayment based on a substantial percentage of the cost of the drug. The number and cost of specialty drugs are expected to increase in the future. New approaches and reimbursement models are emerging to manage the high cost of new pharmaceuticals. Conclusion. Health-system pharmacists can improve drug safety and manage costs by collaborating with group purchasing organizations, establishing policies for brown bagging, and making efforts to reconcile drug therapy provided in different settings through traditional drug channels and specialty pharmacies or other restricted drug distribution systems.
ACCESSION #
48713206

 

Related Articles

  • Ensuring drug safety in health systems: Role of the Food and Drug Administration Amendments Act of 2007, risk evaluation and mitigation strategies, and restricted drug distribution systems.  // American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS21 

    The article presents several learning objectives and assessment questions for readers of the journal upon completion of the articles in the November 15, 2009, issue. The article states that readers should be able to discuss various provisions of the U.S. Food and Drug Administration Amendments...

  • The Food and Drug Administration Amendments Act of 2007: Drug safety and health-system pharmacy implications. Shane, Rita // American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS2 

    The article examines the implications upon drug safety and health-system pharmacies as a result of the implementation of the U.S. Food and Drug Administration Amendments Act (FDAAA) of 2007. The author asserts that the FDAAA enhanced the authority of the FDA during postmarketing of drugs, which...

  • The Food and Drug Administration Amendments Act of 2007: Drug safety and health-system pharmacy implications. Meyer, Brian M. // American Journal of Health-System Pharmacy;12/15/2009 Supplement, pS3 

    Purpose. To describe the drug safety provisions of the Food and Drug Administration Amendments Act (FDAAA) of 2007, including risk evaluation and mitigation strategies (REMS), and the implications for health-system pharmacists. Summary. The FDAAA grants FDA new authorities to require...

  • APhA-APRS. Williams, Karl G. // Journal of the American Pharmacists Association: JAPhA;Sep/Oct2010, Vol. 50 Issue 5, p560 

    The article discusses new provisions in the United States Food and Drug Administration Amendments Act (the Act) . The Act authorizes the Food and Drug Administration (FDA) to require submission of a proposed risk evaluation and mitigation strategies (REMS) by manufacturers any time that risks of...

  • Fresh from the biologic pipeline. Osborne, Randall // Nature Biotechnology;Mar2009, Vol. 27 Issue 3, p222 

    The article discusses the approval of numerous molecular entities by the U.S. Food and Drug Administration (FDA), which took place in 2008. Many new rules have stemmed from legislation concerning the government entity, including the Food and Drug Administration Amendments Act (FDAAA) that was...

  • OIG: Who Knows Whether REMS Improve Drug Safety? Serebrov, Mari // BioWorld Today;2/14/2013, Vol. 24 Issue 31, p1 

    The article offers the author's insights on the effectiveness of risk evaluation and mitigation strategies (REMS) in assuring drug safety. The author says that based on the Office of the Inspector General's (OIG's) report on February 13, 2013, there is no reliable method identified to assess the...

  • Record high drug shortages warrant FDA policy changes, AHA tells House health panel.  // AHA News;7/11/2011, Vol. 47 Issue 14, p1 

    The article reports on the action of the U.S. Food and Drug Administration to avoid drug shortages, such as the implementation of the Prescription Drug User Fee Act and the Preserving Access to Life Saving Medications Act.

  • FDA May Alter Rules on Drug Combos.  // Chain Drug Review;9/27/2010, Vol. 32 Issue 16, p93 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to change rules enabling manufacturers greater leeway in developing drug combinations.

  • FDA Actions.  // CenterWatch Monthly;Nov2015, Vol. 22 Issue 11, p16 

    A chart is presented depicting a sampling of the U.S. Food and Drug Administration (FDA) regulatory actions taken during October 2015.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics